ABIVAX |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.16 EUR | +0.28% |
|
+2.76% | +44.20% |
| Apr. 11 | Morgan Stanley Adjusts Price Target on Abivax to $16 From $15, Maintains Equalweight Rating | MT |
| Apr. 08 | Transcript : ABIVAX Société Anonyme, 2023 Earnings Call, Apr 08, 2024 |
Evolution of the average Target Price on Abivax
Price target over the last 5 years
History of analyst recommendation changes
ee570e3a7b0189cd6ea.0urERivpE1xZQW44NOti-SNw9ZBan98ZQP-OZ1wTB94.5Zq0F0y8JAQ7MAtABJ8UzmtIxM8i2Ip4H8y-NAViQ4e8mo9xbrZjCBQvLw~e00ef23f3ef2d92915a0d2fcc750f394
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
14.16
EUR
Average target price
35.74
EUR
Spread / Average Target
+152.40%
High Price Target
65
EUR
Spread / Highest target
+359.04%
Low Price Target
17.7
EUR
Spread / Lowest Target
+25.00%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Abivax
| Morgan Stanley |
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ABVX Stock
- Consensus Abivax
